45 INTerpath-004: A phase 2, randomized, double-blind study of pembrolizumab with V940 (mRNA-4157) or placebo in the adjuvant treatment of renal cell carcinoma

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Oncologist

Topics

Medicine

Cancer Oncology

Pathology

Internal Medicine

Urology

Show all topics

DOI

10.1093/oncolo/oyae181.022

License

CC-BY-NC